To further mitigate confounding from medication use, we included the use of TNF-alpha inhibitors, ixekizumab, ustekinumab, methotrexate, JAK inhibitors, guselkumab and several other common psoriasis and PsA therapies as covariates in our PSM approach. Here, TNF is linked to psoriasis.